Business Context and Reporting Period
Company: Mineralys Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 2, 2025
Reporting Period: Event date of September 2, 2025
The Company is an emerging growth company incorporated in Delaware. This filing reports a specific corporate event regarding its equity financing arrangements rather than periodic financial results.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
Termination of ATM Prospectus Supplement: On September 2, 2025, the Company notified BofA Securities, Inc. and Evercore Group L.L.C. that it is suspending the use of and terminating the prospectus supplement dated April 11, 2024. This supplement relates to the At-The-Market (ATM) Equity Offering Sales Agreement dated March 21, 2024.
- Impact on Sales: The Company will not make any sales of common stock under the Sales Agreement until a new prospectus supplement is filed with the SEC.
- Agreement Status: The underlying Sales Agreement remains in full force and effect despite the termination of the specific prospectus supplement.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates a strategic pause in equity sales via the ATM facility. No forward-looking guidance, revenue outlook, or specific risk factors beyond the suspension of sales were disclosed in this document.
Unusual Items: The suspension of the ATM facility is the primary unusual item reported. This action halts the Company's ability to raise capital through this specific mechanism until regulatory documentation is updated.
Investor Verification Checklist
- Verify the current cash position and runway of the Company given the suspension of the ATM facility.
- Monitor for the filing of a new prospectus supplement to resume ATM sales.
- Review the original Sales Agreement (Exhibit 1.2 to Form S-3 filed March 21, 2024) to understand remaining terms and obligations.
- Check for any concurrent announcements regarding alternative financing strategies or capital needs.